Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial

Key Points

• This research aims to assess the efficacy and safety of GS1-144 in treating moderate-to-severe vasomotor symptoms in postmenopausal Chinese women.
• Conducted a randomized, double-blind, placebo-controlled phase 2 trial.
• Included postmenopausal women experiencing moderate-to-severe vasomotor symptoms.
• Compared the effects of GS1-144 with a placebo.
• GS1-144 significantly reduced the frequency of vasomotor symptoms.
• Participants reported a decrease in the severity of symptoms.
• The treatment was well tolerated with no severe side effects.